search
Back to results

Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome

Primary Purpose

Rett Syndrome

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Administration of a high dose of desipramine
Administration of a low dose of desipramine
Administration of a placebo
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rett Syndrome focused on measuring Rett syndrome

Eligibility Criteria

4 Years - 18 Years (Child, Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Rett syndrome;
  • Girls weighing less than 60 kg;
  • Respiratory alteration;
  • Diagnosis of Rett syndrome confirmed by MECP2 genotyping (Xq28).

Exclusion Criteria:

  • Boys;
  • Pregnancy and breath feeding;
  • Case history of status epilepticus;
  • Patient treated by IMAO or sultopride;
  • Hepatic or renal failure.

Sites / Locations

  • Assistance Publique - Hopitaux de Marseille

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Desipramine high dose

Desipramine low dose

Placebo

Arm Description

12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight : From 15 to 25 kg : 50 mg ; From 26 to 35 kg : 75 mg ; From 36 to 45 kg : 100 mg ; > 46 kg : 150 mg.

12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight : From 15 to 25 kg : 25 mg ; From 26 to 35 kg : 50 mg ; From 36 to 45 kg : 75 mg ; > 46 kg : 100 mg.

12 patients with Rett syndrome receiving a daily dose of placebo.

Outcomes

Primary Outcome Measures

To study the efficacy of the desipramine on the respiratory disturbations

Secondary Outcome Measures

To study the safety of the desipramine in the studied population

Full Information

First Posted
October 6, 2009
Last Updated
July 25, 2018
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT00990691
Brief Title
Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome
Official Title
Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
February 17, 2009 (Actual)
Primary Completion Date
August 11, 2014 (Actual)
Study Completion Date
August 21, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Rett syndrome is a neurodevelopmental disorder characterized by cognitive impairment, communication dysfunction, stereotypic movement disorder, and growth failure. Rett syndrome is caused by mutations in the Methyl CpG-Binding Protein-2 (MECP2) gene and has no treatment. A mouse experimental model of Rett syndrome created by genetic invalidation of the MECP2 gene is available. It had been then observed that adult MECP2-deficient mice show respiratory alterations and found that endogenous noradrenaline helps to maintain a normal respiratory rhythm. Desipramine, a selective inhibitor of norepinephrine reuptake, seems to be efficient to reduce the respiratory alteration occuring in MECP2-deficient mice (Insem patent 2005, Villard and Roux 2006). The aim of the study is to evaluate these obtained results in MECP2-deficient mice on patients with Rett syndrome.
Detailed Description
Rett syndrome is a neurodevelopmental disorder characterized by cognitive impairment, communication dysfunction, stereotypic movement disorder, and growth failure. The diagnosis of Rett syndrome is based on consensus clinical criteria. Rett syndrome is caused by mutations in the Methyl CpG-Binding Protein-2 (MECP2) gene and has no treatment. Only a few improved cases have been reported concerning buspirone (Andaku, 2005, 1 patient), topiramate (Goyal, 2004, 8 patients), diazepam (Kurihara, 2001, 1 patient) and carnitin (Plochl, 2004, 1 patient). Only one randomized study versus placebo has been published about a treatment by naltrexone including 25 patients. A light improvement of respiratory parameters was then observed with a deterioration of the cognitive function (Percy, 2004). A mouse experimental model of Rett syndrome created by genetic invalidation of the MECP2 gene is available. It had been then observed that adult MECP2-deficient mice show respiratory alterations and found that endogenous noradrenaline helps to maintain a normal respiratory rhythm. Desipramine, a selective inhibitor of norepinephrine reuptake, seems to be efficient to reduce the respiratory alteration occuring in MECP2-deficient mice (Insem patent 2005, Villard and Roux 2006). The aim of the study is to evaluate these obtained results in MECP2-deficient mice on patients with Rett syndrome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rett Syndrome
Keywords
Rett syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Desipramine high dose
Arm Type
Experimental
Arm Description
12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight : From 15 to 25 kg : 50 mg ; From 26 to 35 kg : 75 mg ; From 36 to 45 kg : 100 mg ; > 46 kg : 150 mg.
Arm Title
Desipramine low dose
Arm Type
Experimental
Arm Description
12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight : From 15 to 25 kg : 25 mg ; From 26 to 35 kg : 50 mg ; From 36 to 45 kg : 75 mg ; > 46 kg : 100 mg.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
12 patients with Rett syndrome receiving a daily dose of placebo.
Intervention Type
Drug
Intervention Name(s)
Administration of a high dose of desipramine
Intervention Description
Administration of a daily dose of desipramine correlated with the patient's weight : From 15 to 25 kg : 50 mg ; From 26 to 35 kg : 75 mg ; From 36 to 45 kg : 100 mg ; > 46 kg : 150 mg.
Intervention Type
Drug
Intervention Name(s)
Administration of a low dose of desipramine
Intervention Description
Administration of a daily dose of desipramine correlated with the patient's weight : From 15 to 25 kg : 25 mg ; From 26 to 35 kg : 50 mg ; From 36 to 45 kg : 75 mg ; > 46 kg : 100 mg.
Intervention Type
Drug
Intervention Name(s)
Administration of a placebo
Intervention Description
Administration of a daily dose of placebo
Primary Outcome Measure Information:
Title
To study the efficacy of the desipramine on the respiratory disturbations
Time Frame
2 years
Secondary Outcome Measure Information:
Title
To study the safety of the desipramine in the studied population
Time Frame
2 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Rett syndrome; Girls weighing less than 60 kg; Respiratory alteration; Diagnosis of Rett syndrome confirmed by MECP2 genotyping (Xq28). Exclusion Criteria: Boys; Pregnancy and breath feeding; Case history of status epilepticus; Patient treated by IMAO or sultopride; Hepatic or renal failure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Josette Mancini
Organizational Affiliation
Assistance Publique Hopitaux De Marseille
Official's Role
Principal Investigator
Facility Information:
Facility Name
Assistance Publique - Hopitaux de Marseille
City
Marseille
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
29468173
Citation
Mancini J, Dubus JC, Jouve E, Roux JC, Franco P, Lagrue E, Castelnau P, Cances C, Chaix Y, Rougeot-Jung C, Cornu C, Desportes V, Vallee L, Bahi-Buisson N, Truillet R, Attolini L, Villard L, Blin O, Micallef J. Effect of desipramine on patients with breathing disorders in RETT syndrome. Ann Clin Transl Neurol. 2017 Dec 27;5(2):118-127. doi: 10.1002/acn3.468. eCollection 2018 Feb.
Results Reference
derived

Learn more about this trial

Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome

We'll reach out to this number within 24 hrs